PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Pefloxacin→

Pefloxacin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
70458-92-3
Molecular formula
C17H20FN3O3
Molecular weight
333.36 g/mol
Drug class
Fluoroquinolone antibacterialbacterial DNA gyrase and topoisomerase IV inhibitor
Mechanism of action
Inhibits bacterial type II topoisomerases, DNA gyrase and topoisomerase IV, trapping enzyme-DNA cleavage complexes and preventing DNA replication and transcription. This produces bactericidal activity against susceptible Gram-negative and Gram-positive organisms.
Indications / reported uses
  • Historically used for susceptible systemic bacterial infections, including selected urinary, gastrointestinal and respiratory infections, where authorised.
  • Use is restricted or withdrawn in some jurisdictions because of potentially disabling and long-lasting fluoroquinolone adverse effects; follow current local authorisation and product information.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/51081 · https://antibioticdb.com/AdbCompoundDisplayForward?id=2039 · https://www.ema.europa.eu/en/news/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Pefloxacin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pefloxacin Permitted Daily Exposure (PDE) report (the Pefloxacin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pefloxacin Occupational Exposure Limit (OEL) report (the Pefloxacin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.